Related Experiment Videos
Key current clinical issues in alpha-1 antitrypsin deficiency
1Department of Pulmonary and Critical Care Medicine, A90, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland OH 44195, USA. stollej@ccf.org.
Respiratory Care
|December 4, 2003
Summary
Alpha-1 antitrypsin deficiency (AATD) is under-recognized. New standards recommend wider testing and consider augmentation therapy for patients with airflow obstruction, improving AATD diagnosis and care.
Area of Science:
- Pulmonology
- Genetics
- Internal Medicine
Background:
- Alpha-1 antitrypsin deficiency (AATD) is a prevalent genetic disorder often overlooked.
- Respiratory therapists play a crucial role in managing AATD.
- Recent international guidelines address AATD diagnosis and management.
Purpose of the Study:
- To summarize the international evidence-based standards for AATD diagnosis and management.
- To highlight recommendations for increased AATD screening.
- To review evidence on the efficacy of intravenous AATD augmentation therapy.
Main Methods:
- Review of an international evidence-based standards document.
- Analysis of evidence regarding the clinical efficacy of intravenous AAT. augmentation therapy.
- Synthesis of recommendations for AATD diagnosis and treatment.
Main Results:
- The standards document advocates for broader AATD testing to benefit more patients.
- Evidence suggests clinical efficacy of AAT augmentation therapy, particularly in moderate airflow obstruction.
- Intravenous augmentation therapy is recommended in specific clinical situations.
Conclusions:
- Increased AATD screening is recommended to identify affected individuals.
- Intravenous augmentation therapy is supported by current evidence for specific patient groups.
- Adherence to these standards can improve outcomes for individuals with AATD.